This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced disappointing top-line results from the CheckMate-214 trial on Opdivo in renal cell carcinoma.
Will Nektar's (NKTR) Candidates Enhance Growth in 2017?
by Zacks Equity Research
Nektar Therapeutics (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.
Impax Laboratories (IPXL) Q2 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
Impax Laboratories (IPXL) reported positive second-quarter results with earnings and sales both beating estimates. The company has strengthened its generic portfolio with additional approvals during the quarter.
Valeant (VRX) Beats Q2 Earnings, Sales in Line, Trims View
by Zacks Equity Research
Valeant's (VRX) second-quarter results were encouraging but the company trimmed its guidance due to recent divestitures.
Inovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Inovio Pharmaceuticals (INO) reports narrower-than-expected loss with revenue beating estimates. Moreover, the top line significantly increases year over year.
Ironwood (IRWD) Q2 Loss Widens, Revenues Miss, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) second-quarter results were dismal, missing sales and earnings estimates.
Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals
by Arpita Dutt
Pfizer's (PFE) results were mixed while Teva had a dismal quarter with the company missing estimates as well as cutting its outlook and guidance.
The Zacks Analyst Blog Highlights: Merck, Citigroup, AstraZeneca, HSBC and Sprint
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Citigroup, AstraZeneca, HSBC and Sprint
Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More
by Arpita Dutt
Companies like AstraZeneca (AZN) and Lilly saw their shares fall after the release of second quarter results.
AstraZeneca (AZN) Beats on Q2 Earnings, Falls on Failed Study
by Zacks Equity Research
AstraZeneca PLC (AZN) reported second-quarter 2017 core earnings of 87 cents per ADS, which beat the Zacks Consensus Estimate of 41 cents. Failure in lung cancer study on Imfinzi however pulled the stock down.
Merck (MRK) Beats on Q2 Earnings and Sales, Keeps 2017 View
by Zacks Equity Research
Merck & Co., Inc. (MRK) beat estimates for both earnings and sales in Q2 mainly backed by strong sales of PD-1 inhibitor, Keytruda.
Ironwood (IRWD) Reports Positive Data on Reflux Candidate
by Zacks Equity Research
Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease.
Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod
by Arpita Dutt
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.
AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise
by Zacks Equity Research
AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).
Arena Announces Secondary Stock Worth $150M (revised)
by Zacks Equity Research
Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions.
Pfizer Xeljanz Label Expansion Application Accepted by FDA
by Zacks Equity Research
Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) for Xeljanz has been accepted for review by the FDA.
J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab
by Zacks Equity Research
Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed by the trade name of Tremfya.
Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.
by Arpita Dutt
Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.
Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion
by Zacks Equity Research
We issued an updated research report on Boulder, CO-based Clovis Oncology, Inc. (CLVS) on Jul 12.
Lilly Settles Patent Litigation on Cialis with Generic Firms
by Zacks Equity Research
Eli Lilly & Company (LLY) announced that it has entered into an agreement with generic companies to settle a patent relating to its erectile dysfunction drug Cialis (tadalafil).
Mallinckrodt to Pay $35M for Controlled Substances Probe
by Zacks Equity Research
Mallinckrodt plc (MNK) recently finalized the agreement which it had reached with the U.S. Drug Enforcement Administration (DEA) and the U.S. Attorneys' Offices (USAOs) for the Eastern District of Michigan and the Northern District of New York.
Arena Announces Secondary Stock Offering of 150M Shares
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) plans to offer and sell 150 million shares of its common stock, subject to customary closing conditions.
BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer
by Zacks Equity Research
BioLineRx Ltd. (BLRX) announced that its partner Genentech, has initiated a phase Ib/II study, evaluating BL-8040 in combination Tecentriq (atezolizumab) for treatment of patients with metastatic pancreatic ductal adenocarcinoma.
3 Large Cap Pharma Stocks to Buy Now
by Ryan McQueeney
The healthcare sector has dominated headlines this year thanks to promises from the GOP and the Trump administration related to repealing and replacing Obamacare. This uncertainty has not led to weak trading, and large cap pharma stocks have been among some of the biggest gainers this year. Check out these three large cap pharma stocks to buy now!
Lilly's Breast Cancer Drug Gets Priority Review Status by FDA
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that its new drug application for its pipeline candidate, abemaciclib , has been accepted for priority review by the FDA for patients with advanced breast cancer.